Kalydeco 25 mg granules in sachet clinical trials

A Phase 3, Open-label Study Evaluating the Pharmacokinetics, Safety, and Tolerability of Elexacaftor/Tezacaftor/Ivacaftor in Cystic Fibrosis Subjects 12 to Less Than 24 Months of Age

This study is testing a new combination medicine for babies and toddlers aged 12 to 24 months with Cystic Fibrosis. Researchers want to ensure the medicine is safe and well-tolerated, and how it moves through the body.